EB RESEARCH PARTNERSHIP INC
Annual Giving
$4.5M-17% YoY
Grants
20
Median Grant
$135K
Organizations Funded
12
Is this foundation right for you?
SciRise maps the network of who funds whom to surface your next funders. Enter your nonprofit to check your fit.
Foundation Overview
Mission
The largest 501(c)(3) nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa, a group of devastating and life-threatening skin disorders that affect children from birth; bold audacious goal to heal and cure EB by 2030
Focus Areas
Grant Types
Funded Initiatives
Since founding, raised over $40 million and funded over 100 EB research projects. Clinical trials grew from 2 in 2010 to over 30 today. EB Clinical Characterization and Outcomes Database has over 800 patients enrolled. Three FDA-approved treatments in past two years.
How to Apply
Submit Letter of Interest (LOI) which will be evaluated by Scientific Advisory Board. Based on evaluation, Executive Board selects projects for funding. Projects should result in EB therapies with commercialization aim within 1-4 years. Clinical trial work strongly preferred. Second grant cycle 2025 deadline: September 4th at 11:59pm ET.
Based on publicly available information from the foundation's 990 filings and website.
Giving History
$4.5M
Grants
20
Median
$135K
States
10
$5.4M
Grants
18
Median
$137K
States
10
$5.4M
Grants
16
Median
$218K
States
11
Grant Size Distribution
$135K
Typical Grant (Median)
$7K
Smallest
$38K
25th Pctile
$299K
75th Pctile
$951K
Largest
Excludes grants ≤ $5K. Half fall between $38K and $299K.
Largest Recent Grants
$951K
2024
UNIVERSITY OF COLORADO
CO · TO FUND RESEARCH TO FIND A CURE FOR EB
$948K
2024
NORTHWESTERN UNIVERSITY
IL · TO FUND RESEARCH TO FIND A CURE FOR EB
$385K
2024
CHILDREN'S HOSPITAL OF PHILADELPHIA
PA · TO FUND RESEARCH TO FIND A CURE FOR EB
$347K
2024
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
OH · TO FUND RESEARCH TO FIND A CURE FOR EB
$303K
2024
Foreign Grants - EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM
NONSENSE READTHROUGH USING GENTAMICIN OR ELX-02 IN COMBINATION WITH POTENTIATOR COMPOUNDS FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA AND JUNCTIONAL EPIDERMOLYSIS BULLOSA
Geographic Focus
Top states by total grant dollars. Based on IRS filing data.
Financial Overview
Grants paid shown as percentage of total assets
Data sourced from IRS 990 and 990-PF filings and publicly available foundation websites. Grant data, financial figures, and organizational details reflect historical filings and may not represent current operations or funding priorities. Verify directly with the foundation before applying. See an issue? Let us know.